Rhumbline Advisers Allogene Therapeutics, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

A detailed history of Rhumbline Advisers transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 164,508 shares of ALLO stock, worth $524,780. This represents 0.0% of its overall portfolio holdings.

Number of Shares

164,508

Previous 152,035 8.2%

Holding current value

$524,780

Previous $679,000 43.59%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$2.23 - $4.38 $27,814 - $54,631	12,473 Added 8.2%	164,508 $383,000
Q1 2024 May 09, 2024	BUY	$2.92 - $5.63 $17,736 - $34,196	6,074 Added 4.16%	152,035 $679,000
Q4 2023 Feb 08, 2024	BUY	$2.28 - $3.5 $15,540 - $23,856	6,816 Added 4.9%	145,961 $468,000
Q3 2023 Nov 09, 2023	SELL	$3.17 - $5.96 $16,154 - $30,372	-5,096 Reduced 3.53%	139,145 $441,000
Q2 2023 Aug 08, 2023	BUY	$4.53 - $6.74 $67,990 - $101,160	15,009 Added 11.61%	144,241 $716,000
Q1 2023 May 11, 2023	BUY	$4.92 - $8.21 $18,351 - $30,623	3,730 Added 2.97%	129,232 $638,000
Q4 2022 Feb 14, 2023	SELL	$5.62 - $11.11 $18,945 - $37,451	-3,371 Reduced 2.62%	125,502 $789,000
Q3 2022 Nov 10, 2022	BUY	$10.32 - $17.28 $104,995 - $175,806	10,174 Added 8.57%	128,873 $1.39 Million
Q2 2022 Aug 11, 2022	BUY	$6.78 - $12.28 $232,425 - $420,970	34,281 Added 40.61%	118,699 $1.35 Million
Q1 2022 May 12, 2022	SELL	$7.65 - $15.29 $42,097 - $84,140	-5,503 Reduced 6.12%	84,418 $769,000
Q4 2021 Feb 10, 2022	SELL	$13.13 - $24.52 $11,121 - $20,768	-847 Reduced 0.93%	89,921 $1.34 Million
Q3 2021 Nov 12, 2021	BUY	$21.01 - $27.64 $61,727 - $81,206	2,938 Added 3.35%	90,768 $2.33 Million
Q2 2021 Aug 05, 2021	BUY	$23.49 - $35.8 $621,733 - $947,554	26,468 Added 43.13%	87,830 $2.29 Million
Q1 2021 May 06, 2021	SELL	$25.79 - $39.02 $155,616 - $235,446	-6,034 Reduced 8.95%	61,362 $2.17 Million
Q4 2020 Feb 10, 2021	BUY	$25.24 - $43.45 $81,575 - $140,430	3,232 Added 5.04%	67,396 $1.7 Million
Q3 2020 Nov 12, 2020	SELL	$32.38 - $44.96 $382,925 - $531,696	-11,826 Reduced 15.56%	64,164 $2.42 Million
Q2 2020 Aug 13, 2020	BUY	$18.39 - $54.04 $393,656 - $1.16 Million	21,406 Added 39.22%	75,990 $3.25 Million
Q1 2020 May 06, 2020	BUY	$18.22 - $28.25 $24,779 - $38,420	1,360 Added 2.56%	54,584 $1.06 Million
Q4 2019 Feb 05, 2020	BUY	$24.82 - $31.4 $45,023 - $56,959	1,814 Added 3.53%	53,224 $1.38 Million
Q3 2019 Oct 23, 2019	BUY	$26.11 - $32.99 $3,080 - $3,892	118 Added 0.23%	51,410 $1.4 Million
Q2 2019 Aug 14, 2019	BUY	$25.56 - $31.09 $509,768 - $620,058	19,944 Added 63.62%	51,292 $1.38 Million
Q1 2019 May 01, 2019	BUY	$24.82 - $32.54 $13,899 - $18,222	560 Added 1.82%	31,348 $906,000
Q4 2018 Jan 31, 2019	BUY	$22.5 - $33.3 $692,730 - $1.03 Million	30,788 New	30,788 $829,000

Others Institutions Holding ALLO

# of Institutions

172

Shares Held

131M

Call Options Held

94.3K

Put Options Held

112K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $459M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Allogene Therapeutics, Inc. Transaction History